Abiomed (ABMD) Tops Q4 EPS by 1c

Abiomed (NASDAQ: ABMD) reported Q4 EPS of $1.11, ex-gain, $0.01 better than the analyst estimate of $1.10. Revenue for the quarter came in at $241 million versus the consensus estimate of $230.38 million.

GUIDANCE:

Abiomed sees FY2022 revenue of $0.99-1.03 billion, versus the consensus of $0.998 billion.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'